Genomic Health signs colorectal cancer test deal
Bristol-Myers Squibb and ImClone Systems have signed a deal with Genomic Health (cancer diagnostics) to create a test that can predict colorectal cancer patients' responses to Erbitux (cetuximab).
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com